{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:31:19Z","timestamp":1793431879516,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Novartis Pharma Schweiz"},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.leukres.2014.03.023","type":"journal-article","created":{"date-parts":[[2014,4,26]],"date-time":"2014-04-26T09:16:07Z","timestamp":1398503767000},"page":"764-772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Large-scale imatinib dose\u2013concentration\u2013effect study in CML patients under routine care conditions"],"prefix":"10.1016","volume":"38","author":[{"given":"Verena","family":"Gotta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Bouchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Widmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schuld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent A.","family":"Decosterd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Buclin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois-Xavier","family":"Mahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Csajka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Molimard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2014.03.023_bib0005","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.03.023_bib0010","first-page":"1126","article-title":"International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.leukres.2014.03.023_bib0015","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/leu.2011.217","article-title":"Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy","volume":"26","author":"Shami","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.03.023_bib0020","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.blre.2011.09.001","article-title":"Managing resistance in chronic myeloid leukemia","volume":"25","author":"Roychowdhury","year":"2011","journal-title":"Blood Rev"},{"key":"10.1016\/j.leukres.2014.03.023_bib0025","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2009.88","article-title":"Pharmacokinetic\/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia","volume":"23","author":"Cortes","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.03.023_bib0030","first-page":"758","article-title":"Bulletin Board EUTOS for chronic myeloid leukemia shows improved management and dose optimization is required","volume":"4","year":"2008","journal-title":"Future Oncol"},{"key":"10.1016\/j.leukres.2014.03.023_bib0035","series-title":"Path to cure: about the subproject pharmacological monitoring","author":"European Treatment and Outcome Study (EUTOS)","year":"2011"},{"key":"10.1016\/j.leukres.2014.03.023_bib0040","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/FTD.0b013e31823cdec9","article-title":"The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors","volume":"34","author":"Teng","year":"2012","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.leukres.2014.03.023_bib0045","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.03.023_bib0050","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.03.023_bib0055","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.cca.2009.10.007","article-title":"Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: comparison with LC\u2013MS\/MS","volume":"411","author":"Roth","year":"2010","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.leukres.2014.03.023_bib0060","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cca.2011.02.023","article-title":"Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC\/MS\u2013MS","volume":"412","author":"Bouchet","year":"2011","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.leukres.2014.03.023_bib0065","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/FTD.0b013e31815c16f5","article-title":"Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring","volume":"29","author":"Zhou","year":"2007","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.leukres.2014.03.023_bib0070","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","article-title":"Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib","volume":"117","author":"Haouala","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.03.023_bib0075","series-title":"Table des interaction m\u00e9dicamenteuses et cytochromes P450","author":"Centre d\u2019informations th\u00e9rapeutique et de pharmacovigilance \u2013 H\u00f4pitaux Universitaires de Gen\u00e8ve","year":"2009"},{"key":"10.1016\/j.leukres.2014.03.023_bib0080","doi-asserted-by":"crossref","first-page":"5932","DOI":"10.1021\/jm8003152","article-title":"Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1","volume":"51","author":"Ahlin","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.leukres.2014.03.023_bib0085","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib","volume":"108","author":"White","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.03.023_bib0090","series-title":"Drug development and drug interactions table of substrates, inhibitors and inducers","author":"FDA U.S. Food and Drug Administration","year":"2011"},{"key":"10.1016\/j.leukres.2014.03.023_bib0095","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00280-004-0876-0","article-title":"Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC soft tissue and bone sarcoma group","volume":"55","author":"Judson","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.leukres.2014.03.023_bib0100","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s10637-011-9633-5","article-title":"Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure","volume":"30","author":"Yoo","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.leukres.2014.03.023_bib0105","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00280-008-0730-x","article-title":"Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults","volume":"63","author":"Menon-Andersen","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.leukres.2014.03.023_bib0110","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2014.03.023_bib0115","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00228-009-0779-4","article-title":"Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example","volume":"66","author":"Li-Wan-Po","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.leukres.2014.03.023_bib0120","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1111\/j.1349-7006.2010.01643.x","article-title":"Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study","volume":"101","author":"Ishikawa","year":"2010","journal-title":"Cancer Sci"},{"key":"10.1016\/j.leukres.2014.03.023_bib0125","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3324\/haematol.2011.056721","article-title":"Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy","volume":"97","author":"Pemmaraju","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2014.03.023_bib0130","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/fcp.12007","article-title":"Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory","volume":"27","author":"Bouchet","year":"2013","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.leukres.2014.03.023_bib0135","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2012-10-462291","article-title":"Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML","volume":"121","author":"Branford","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.03.023_bib0140","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.03.023_bib0145","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2014.03.023_bib0150","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/FTD.0b013e318284ef11","article-title":"Systematic review of population pharmacokinetic analyses of imatinib and relationships with treatment outcomes","volume":"35","author":"Gotta","year":"2013","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.leukres.2014.03.023_bib0155","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1158\/1078-0432.CCR-12-0490","article-title":"A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients","volume":"18","author":"Eechoute","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2014.03.023_bib0160","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1158\/1078-0432.CCR-12-3445","article-title":"Long-term prospective population PK study in GIST patients-letter","volume":"19","author":"Chatelut","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2014.03.023_bib0165","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2125.2005.02372.x","article-title":"Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study","volume":"60","author":"Schmidli","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.leukres.2014.03.023_bib0170","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2125.2006.02719.x","article-title":"Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein","volume":"62","author":"Widmer","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.leukres.2014.03.023_bib0175","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.1158\/1078-0432.CCR-05-2596","article-title":"Pharmacokinetic\u2013pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors","volume":"12","author":"Delbaldo","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2014.03.023_bib0180","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1365-2125.2012.04422.x","article-title":"Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours","volume":"75","author":"Haouala","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.leukres.2014.03.023_bib0185","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.2007.13.3819","article-title":"Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group","volume":"26","author":"Gibbons","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2014.03.023_bib0190","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3109\/03602530903491683","article-title":"Hepatic OATP and OCT uptake transporters: their role for drug\u2013drug interactions and pharmacogenetic aspects","volume":"42","author":"Fahrmayr","year":"2010","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.leukres.2014.03.023_bib0195","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/hon.920","article-title":"Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose","volume":"28","author":"Breccia","year":"2010","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.leukres.2014.03.023_bib0200","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","article-title":"Comparison of imatinib 400mg and 800mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study","volume":"113","author":"Baccarani","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.03.023_bib0205","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212614000988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212614000988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:59:17Z","timestamp":1758934757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212614000988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0145212614000988"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2014.03.023","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Large-scale imatinib dose\u2013concentration\u2013effect study in CML patients under routine care conditions","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2014.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}